Arcus Biosciences Inc (RCUS) Stock Price, Quote & News

Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 694 6200

Website: www.arcusbio.com

Address:

3928 Point Eden Way, Hayward, United States

GoParabolic Aug. 1 at 10:49 PM

$RCUS is going to take care of its value soon. $TSLA $AMZN $BTC.X $NVDA

0 · Reply

Randy2979 Aug. 1 at 2:09 AM

$RCUS https://www.fiercebiotech.com/biotech/gsks-anti-tim-3-antibody-flunks-phase-3-trial-anti-tigit-failure-costs-625m

1 · Reply

stcks Jul. 31 at 8:47 PM

$RCUS welcome to pre-commercial biotechs

0 · Reply

Bobes Jul. 31 at 7:38 PM

$RCUS

0 · Reply

Bobes Jul. 30 at 11:44 PM

$RCUS

1 · Reply

MRTunity Jul. 29 at 3:43 PM

$RCUS 🎢 eom

0 · Reply

BardicusDeBursitis Jul. 25 at 12:20 PM

$IOVA well the volume and uptick Tuesday-Wednesday, Mostly Wednesday was shorts covering. The increased volume due to the good catalyst competitive edge with only FDA approval in their space caused them to cover way sooner then expected. Due to those circumstances volume should start returning to normal with this gradually going up over next couple weeks with consolidation along the way. Also if you’ve noticed mid-small cap bio stocks all got oversold beginning of 2025 and majority have only recovered 25-30%. Just look at the one year charts on $RCUS $INO $NVAX and of course $IOVA

1 · Reply

ACES_ Jul. 25 at 1:02 AM

$RCUS I know why

1 · Reply

Bobes Jul. 24 at 11:47 PM

$RCUS not sure why this is under 25 buck. Undervalued on every metric.

1 · Reply

Dameistro Jul. 24 at 5:21 PM

$RCUS sleeping giant here!! Any relevant news increasing valution this thing rocket ships!

0 · Reply

Arcus Biosciences Announces New Employment Inducement Grants

Jul 10, 2025, 8:30 AM EDT - 23 days ago

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

Jun 1, 2025, 10:45 AM EDT - 2 months ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

May 6, 2025, 8:17 PM EDT - 3 months ago

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 3 months ago

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Apr 23, 2025, 4:05 PM EDT - 3 months ago

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Apr 22, 2025, 4:05 PM EDT - 3 months ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Apr 2, 2025, 3:48 PM EDT - 4 months ago

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Feb 26, 2025, 4:35 PM EST - 5 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Feb 25, 2025, 4:05 PM EST - 5 months ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Feb 18, 2025, 6:57 AM EST - 5 months ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025, 6:52 AM EST - 5 months ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Feb 15, 2025, 3:45 PM EST - 6 months ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Feb 10, 2025, 5:00 PM EST - 6 months ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Jan 21, 2025, 4:05 PM EST - 6 months ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Jan 14, 2025, 10:51 PM EST - 7 months ago

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

Jan 13, 2025, 8:00 AM EST - 7 months ago

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Dec 19, 2024, 4:05 PM EST - 8 months ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 6, 2024, 11:39 PM EST - 9 months ago

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:22 PM EST - 9 months ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Nov 5, 2024, 9:00 AM EST - 9 months ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Oct 30, 2024, 9:00 AM EDT - 9 months ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Oct 24, 2024, 7:30 AM EDT - 10 months ago

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Oct 22, 2024, 4:05 PM EDT - 10 months ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Oct 9, 2024, 8:00 AM EDT - 10 months ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Oct 2, 2024, 4:05 PM EDT - 10 months ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

AZN

Sep 23, 2024, 1:53 AM EDT - 11 months ago

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HTGC

Aug 9, 2024, 5:31 PM EDT - 1 year ago

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Aug 9, 2024, 5:21 PM EDT - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Jul 25, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Jul 8, 2024, 6:00 PM EDT - 1 year ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Jun 6, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 2, 2024, 8:00 AM EDT - 1 year ago

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

GILD

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

GILD

May 8, 2024, 9:55 PM EDT - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:02 PM EDT - 1 year ago

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

May 2, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024

Apr 24, 2024, 4:00 PM EDT - 1 year ago

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Apr 23, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

Feb 22, 2024, 2:08 AM EST - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 4:05 PM EST - 1 year ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Feb 7, 2024, 5:00 PM EST - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates

Jan 29, 2024, 6:20 PM EST - 1 year ago

Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%

GILD

Jan 29, 2024, 5:00 PM EST - 1 year ago

Gilead and Arcus Announce Amended Collaboration and Equity Investment

GILD

Jan 16, 2024, 5:00 PM EST - 1 year ago

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Jan 10, 2024, 8:01 AM EST - 1 year ago

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

AGEN BMY CGEN GSK ITOS MRK NVS

Dec 26, 2023, 12:18 PM EST - 1 year ago

20 favorite small-cap stocks for 2024 among Wall Street analysts

ARLO CPRX DGII DVAX GPRE HLX IRWD

GoParabolic Aug. 1 at 10:49 PM

$RCUS is going to take care of its value soon. $TSLA $AMZN $BTC.X $NVDA

0 · Reply

Randy2979 Aug. 1 at 2:09 AM

$RCUS https://www.fiercebiotech.com/biotech/gsks-anti-tim-3-antibody-flunks-phase-3-trial-anti-tigit-failure-costs-625m

1 · Reply

stcks Jul. 31 at 8:47 PM

$RCUS welcome to pre-commercial biotechs

0 · Reply

Bobes Jul. 31 at 7:38 PM

$RCUS

0 · Reply

Bobes Jul. 30 at 11:44 PM

$RCUS

1 · Reply

MRTunity Jul. 29 at 3:43 PM

$RCUS 🎢 eom

0 · Reply

BardicusDeBursitis Jul. 25 at 12:20 PM

1 · Reply

ACES_ Jul. 25 at 1:02 AM

$RCUS I know why

1 · Reply

Bobes Jul. 24 at 11:47 PM

$RCUS not sure why this is under 25 buck. Undervalued on every metric.

1 · Reply

Dameistro Jul. 24 at 5:21 PM

$RCUS sleeping giant here!! Any relevant news increasing valution this thing rocket ships!

0 · Reply

TabJones24 Jul. 24 at 3:00 PM

$RCUS We should all pray for Pam Bondi And her current cornea problem Amen Bizarro Jesus

0 · Reply

stockpicker63 Jul. 23 at 5:15 PM

$RCUS offers higher reward but also higher risk, especially if it fails near its 200-day MA. Use tighter stops. $BLMN is more of a steady, range-break candidate with moderate upside — ideal for traders waiting on volume-validated moves.

1 · Reply

pchr Jul. 22 at 10:09 PM

$RCUS hi longs, anyone would care to share their bullish thesis and if there are any incoming catalysts?

3 · Reply

TabJones24 Jul. 21 at 12:24 PM

$RCUS I love Trump Ankles And all the good things coming from them

0 · Reply

TabJones24 Jul. 18 at 3:38 PM

$RCUS When Trump urinary bag going to burst And we are finally free

0 · Reply

TabJones24 Jul. 18 at 11:58 AM

$RCUS When Trumps ankles catch up to him Do you think Market rallies or falls?

0 · Reply

GoParabolic Jul. 18 at 10:33 AM

$RCUS has great potential to move forward. $TSLA $NVDA $BTC.X $AAPL

0 · Reply

GoParabolic Jul. 16 at 12:53 PM

$RCUS is worth waiting.. $TSLA $AAPL $NVDA $BTC.X

0 · Reply

TheGunnerAB Jul. 16 at 12:45 AM

$RCUS If Dom fails in TIGIT, i don't think it will based on the quick enrollment, then Gilead spent almost $1B to buy 30% of RCUS and have no exclusivity on the other drugs. It seems pretty stupid unless they decide to buy the whole company

0 · Reply

TheGunnerAB Jul. 16 at 12:20 AM

$RCUS So Gilead amended their ownership. Over 8M options just expired and their ownership dropped under 30%

1 · Reply

Kanguru Jul. 15 at 3:36 PM

$RCUS what happened this time smh

0 · Reply

wetsalmon Jul. 15 at 10:38 AM

$RCUS What is this all about…? One man’s opinion? I have not heard this anywhere else…

1 · Reply

Market Cap	969.91M
Revenue (ttm)	258.00M
Net Income (ttm)	-283.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-109.69%
Debt to Equity Ratio	0.09

Volume	805,000
Avg Vol	991,978
Day's Range	N/A - N/A
Shares Out	105.89M
Stochastic %K	21%
Beta	0.89
Analysts	Strong Sell
Price Target	$28.18